Sinovac Biotech, Ltd. (NASDAQ:SVA) reached a new 52-week high during trading on Wednesday . The company traded as high as $7.33 and last traded at $7.30, with a volume of 143800 shares. The stock had previously closed at $7.22.

Separately, BidaskClub cut Sinovac Biotech from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th.

Several institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC boosted its position in shares of Sinovac Biotech by 189.8% during the third quarter. Citadel Advisors LLC now owns 34,193 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 22,393 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Sinovac Biotech during the third quarter valued at $163,000. State Street Corp boosted its position in shares of Sinovac Biotech by 18.5% during the second quarter. State Street Corp now owns 49,281 shares of the biopharmaceutical company’s stock valued at $333,000 after buying an additional 7,711 shares during the last quarter. GLG Partners LP boosted its position in shares of Sinovac Biotech by 144.8% during the second quarter. GLG Partners LP now owns 282,611 shares of the biopharmaceutical company’s stock valued at $1,908,000 after buying an additional 167,165 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Sinovac Biotech by 8.0% during the second quarter. Renaissance Technologies LLC now owns 1,814,300 shares of the biopharmaceutical company’s stock valued at $12,247,000 after buying an additional 134,810 shares during the last quarter. 30.71% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Sinovac Biotech, Ltd. (SVA) Hits New 52-Week High at $7.33” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/sinovac-biotech-ltd-sva-hits-new-52-week-high-at-7-33/1705699.html.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.